Utility of FDG-PET Imaging for Risk Stratification of Pancreatic Neuroendocrine Tumors in MEN1
- 7 March 2017
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (6), 1926-1933
- https://doi.org/10.1210/jc.2016-3865
Abstract
Context: Patients with multiple endocrine neoplasia type 1 (MEN1) are at high risk of malignant pancreatic neuroendocrine tumors (pNETs). Structural imaging is typically used to screen for pNETs but is suboptimal for stratifying malignant potential. Objective: To determine the utility of fluorodeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting the malignant potential of pNETs in MEN1. Design: Retrospective observational study. Setting: Tertiary referral hospital. Patients: Forty-nine adult patients with MEN1 carrying a common MEN1 mutation who underwent 18F-FDG PET/CT for MEN1 surveillance between 1 January 2010 and 30 September 2016. Interventions: Structural and functional imaging (magnetic resonance imaging, CT, ultrasonography, and 18F-FDG PET/CT) and surgical histopathology. Main Outcome Measures: pNET size, behavior, and histopathology. Results: Twenty-five (51.0%) of 49 patients studied had pancreatic lesions on structural imaging. Five (25%) of these had 18F-FDG-PET–avid lesions. In addition, two had solitary FDG-avid liver lesions, and one a pancreatic focus without structural correlate. Eight patients with pNETs underwent surgery (three FDG-avid lesions and five nonavid pNETs). The Ki-67 index was ≥5% in FDG-avid pNETs and <2% in nonavid pNETs. Overall, six of the eight (75%) patients with FDG-avid hepatopancreatic lesions harbored aggressive or metastatic NETs compared with one of 41 patients (2.4%) without hepatopancreatic FDG avidity [P < 0.001; sensitivity; 85.7% (95% confidence interval [CI], 48.7% to 99.3%); specificity, 95.2% (95% CI, 84.2% to 99.2%)]. Conclusion: 18F-FDG PET/CT is an effective screening modality in MEN1 for identifying pNETs of increased malignant potential. Surgical resection is recommended for FDG-avid pNETs.Keywords
This publication has 30 references indexed in Scilit:
- Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow‐up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patientsClinical Endocrinology, 2016
- Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study GroupJournal of Clinical Endocrinology & Metabolism, 2016
- Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1European Journal of Nuclear Medicine and Molecular Imaging, 2016
- Imaging in Multiple Endocrine Neoplasia Type 1: Recent Studies Show Enhanced Sensitivities but Increased ControversiesInternational Journal of Endocrine Oncology, 2016
- Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1The Lancet Diabetes & Endocrinology, 2015
- Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1Journal of the American College of Surgeons, 2015
- Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)Journal of Clinical Endocrinology & Metabolism, 2012
- How should the patient with multiple endocrine neoplasia type 1 (MEN 1) be followed?Clinical Endocrinology, 2009
- Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1).Familial Cancer, 2003
- CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2Journal of Clinical Endocrinology & Metabolism, 2001